Editor's PicksHuge Stride For UK Medicinal Cannabis With £12m...

Huge Stride For UK Medicinal Cannabis With £12m Plan To Cultivate 300,000 Plants A Year


PLANS have been unveiled for a £12m investment to create one of the UK’s largest medicinal cannabis farms – capable of growing 300,000 plants a year.

In a market update, AQSE Growth Market-listed Ananda Developments says it is advanced talks with the Home Office to secure a licence to grow high-THC cannabis in Lincolnshire.

If successful, it hopes to be putting the first plants into the ground next Spring.

Ananda has teamed up with world-renowned Israeli scientist Dr Dedi Meiri, who is currently investigating the anti-inflammatory properties of cannabis for treating coronaviruses.

Annual Harvest Of 200 Tonnes

While the UK medicinal cannabis market is stuck in the slow lane, the potential is huge.

Chief Executive Melissa Sturgess told BusinessCann its 300,000 plants will be capable of delivering an annual harvest of 200 tonnes, when at full capacity.

She said: “We will be growing under proven, successful, natural cycles – under poly-tunnel – with no requirement for artificial heat or light. We plan to ramp-up to full capacity over a six-year period.

“As the market slowly opens up, the UK is being seen very much as a premium jurisdiction for medical cannabis. 

As the market slowly opens up the UK is being seen very much as a premium jurisdiction for medical cannabis.

Ananda Developments Chief Executive Melissa Sturgess

“We are seen increasing interest from many places, including Israel. A lot of spotlight is on the UK and one of the key attractions is the skills of UK scientists. As a UK-based company we aim to help the industry grow and develop.

“The UK has the science and there are UK doctors wanting to prescribe UK-grown medical cannabis instead of importing – a costly and time-consuming process. 

“As we establish a domestic cannabis supply will we then look to the international markets, as we grow.” 

World-Leading Cannabis Scientist Joins The Call

Ananda subsidiary Tiamat Agriculture and JEPCO Group – who previously worked with GW Pharmaceuticals – will deliver the project under the joint venture name DJT Plants.

Cannabis growing in tunnels.

A meeting was held last week between DJT Plants and the MHRA (Medicines and Healthcare products Regulatory Agency). 

The JV partners were supported in the meeting by a 30-minute address from Dr Meiri – one of the world’s foremost researchers in medical cannabis. 

Ms Sturgess added: “The next step is for the Home Office to visit our site and then grant us a Conditional Licence. The approved licence will be for R&D in the first instance.  

“We will grow 65 strains of cannabis to stabilise them, with help from Dr Dedi Meiri’s lab at The Technion in Israel. Then we will move to apply for a commercial licence when we have the strains stabilised.”

Cannabis’ Potential In Battling Coronavirus

Dr Meiri recently launched a new project to assess the  potential of the anti- inflammatory properties of cannabis for treating coronaviruses, and Ananda’s plans are being broadened to stabilise strains of cannabis which may have applicability for the treatment of hyper-inflammation caused by coronaviruses.  

The MHRA is responsible for ensuring medicines and medical devices are safe and it will be responsible for the providing certification of Good Manufacturing Practice and Good Agricultural and Collection Practices approvals for the facility. 

Ananda Developments listed on the junior NEX Exchange – now the AQSE Growth Market – in July 2018, initially raising £930,000 to invest in medicinal cannabis companies.

Ananda’s made its first investment of US $200,000 into iCan Israel-Cannabis, a globally-recognised Israeli company focused on the medical cannabis industry and organiser of CannaTech, the renowned global cannabis event.

This was followed with a further investment into Liberty Herbal Technologies Limited, the developer of hapac, a technology for vaping medicinal cannabis.

Ananda’s announcement follows the sale by Sundial Growers of the Bridge Farm Group – also based in Lincolnshire – for £67m last week. This has been billed as Europe’s largest cannabis deal, to date.

Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.


  1. It sounds amazing but you still have to convince UK GPs that it will benefit people who have no quality of life due to intractable proven pain. These are practitioners who believe your crumbling, ruptured vertebrae and degenerated hip and knees are something you just have to live with, hard luck after 44 years nursing. Think you will find they are not open to even scientifically proven research. Pain control in this country is non existent because they do believe we can control all of it in our heads, after all it is much cheaper and this is what is happening here, budgets before patient care. I have lost faith in our health providers, seen first hand how bad it is. Good luck, I would be willing to be a tester because some days I wish I wasn’t here the pain is so bad, am very bitter that I retired because of work related injuries over all those years with no mechanical aids and when i needed help little was given. GPs are afraid of cannabis, god even hospital consultants won’t easily take research on board.

Comments are closed.

Latest news

Poko Innovations, Inc. Receives Validation And Authorization To Sell 44 Items In The UK

POKO Innovations an award-winning UK-based collection of CBD-focused companies that bring innovative, inspiring solutions to the CBD industry through...

Intercure Posts More Record Results But Says It ‘Could Do So Much More’ If It Had More Supply

INTERCURE has released another set of ‘all time record quarterly’ results, seeing both revenues and profits skyrocket year-on-year.  Despite its...

Stenocare Delivers First Product Batch To The Danish Market

STENOCARE delivers the first product batch of their THC Oil to the Danish market. This means that the product is...

Chill Brands Targets Near £4m Capital Raise To Fund Fresh Strategy & £1.3m Chill.com Domain

CHILL Brands’ shareholders have voted in favour of plans for a new £3.5m fundraise alongside a separate £484,000 open...

Cellular Goods Makes More Major Changes To Board In First Update Since Ingestibles Were Pulled (UPDATED)

Cellular Goods has released its first significant update since announcing that its ingestibles products were not legally allowed to...

European Cannabis Stocks Review: Akanda Dives Over 80% & Celadon Suffers After Reporting Huge Rise In Losses

This week was another difficult week for London Stock Exchange (LSE) listed cannabis companies, with every one of BusinessCann's...

Must read

Intercure Posts More Record Results But Says It ‘Could Do So Much More’ If It Had More Supply

INTERCURE has released another set of ‘all time record...

Chill Brands Targets Near £4m Capital Raise To Fund Fresh Strategy & £1.3m Chill.com Domain

CHILL Brands’ shareholders have voted in favour of plans...

You might also likeRELATED
Recommended to you